FDA Signals it Will Begin to Look at Caffeine Labeling Regulations – CoffeeTalk

The recent shift in FDA regulatory focus regarding caffeine labeling has emerged from a long-standing gap in how caffeine is disclosed on food and beverage products. Until now, only products explicitly containing caffeine as a standalone ingredient were required to list it on their labels, while naturally occurring caffeine in items like coffee or chocolate went undisclosed, often creating confusion for consumers. In June, the FDA added a new item to its 2026 regulatory agenda: guidance on labeling the caffeine content in foods and beverages, aiming to address the increasing consumption of caffeinated products and promote industry best practices.

This guidance is not an immediate regulatory requirement, as it is still in draft form and not legally binding. The FDA has yet to specify which products will be affected or enforce deadlines for compliance. However, this move signals a shift in regulatory focus and serves as a warning for companies to prepare proactively for potential changes. The timing aligns with increased scrutiny regarding caffeine consumption, particularly concerning marketing to children and teenagers, underscored by recent legal cases involving health impacts from excessive caffeine intake.

The FDA’s agenda is part of a broader initiative focusing on transparency in labeling, including revising criteria for claims like “healthy” and requirements for disclosing artificial colors. This trend indicates a movement towards more specific labeling obligations across the food and beverage sector, suggesting that companies should not cling to outdated practices.

Read More @ BLG